{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:18:32Z","timestamp":1782879512375,"version":"3.54.5"},"reference-count":49,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science & Technology Development Fund of Tianjin Education Commission for Higher Education","award":["2023KJ096"],"award-info":[{"award-number":["2023KJ096"]}]},{"name":"Medical and Health Science and Technology Development Research Center, National Health Commission","award":["WKZX2024CX501224"],"award-info":[{"award-number":["WKZX2024CX501224"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Fraxetin (7,8-dihydroxy-6-methoxycoumarin), a coumarin constituent of Cortex Fraxini (Qinpi) used in traditional Chinese medicine, is metabolised mainly by UGT1A9, but its potential to inhibit UGT enzymes and cause herb\u2013drug interactions (HDIs) is largely unstudied. Methods: Fraxetin and four related coumarins were screened against 11 recombinant human UGTs; isoforms inhibited \u226580% underwent full kinetic analysis with 4-methylumbelliferone as probe. Binding was examined by molecular docking on AlphaFold structures with PLIP, triplicate 100 ns molecular dynamics, and MM\/GBSA and MM\/PBSA free-energy calculations, and interaction risk by FDA 2020 in vitro\u2013in vivo extrapolation (IVIVE). Results: Fraxetin alone inhibited both UGT1A1 and UGT1A9 by &gt;80% and was characterised in detail, acting as a mainly competitive mixed-type inhibitor (UGT1A1 IC50 15.99 \u03bcM, Ki 8.32 \u03bcM; UGT1A9 IC50 8.44 \u03bcM, Ki 5.90 \u03bcM). A structure\u2013activity comparison identified a dual-element pharmacophore comprising the C-6 methoxy group and the 7,8-dihydroxycoumarin aglycone. MM\/GBSA favoured UGT1A9 over UGT1A1 (\u0394\u0394G = \u22124.06 kcal\/mol, p = 0.005), concordant with the kinetic ranking. IVIVE predicted a borderline systemic signal (R1 &gt; 1.02) but an intestinal R1,gut approximately five- to seven-fold above the high-risk threshold of 11 after capping the luminal concentration at fraxetin aqueous solubility. Conclusions: This is the first characterisation of fraxetin as a moderate-potency inhibitor of UGT1A1 and UGT1A9 and points to a previously under-recognised herb\u2013drug interaction risk concentrated in the intestinal lumen rather than systemically; the finding constitutes an interaction signal requiring clinical confirmation rather than an established risk.<\/jats:p>","DOI":"10.3390\/ph19060968","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:06:34Z","timestamp":1782875194000},"page":"968","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fraxetin Inhibits UGT1A1 and UGT1A9 Activities In Vitro: Inhibition Kinetics, Molecular Dynamics Simulation, and Prediction of Herb\u2013Drug Interaction Risk"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-7656","authenticated-orcid":false,"given":"Jinqian","family":"Chen","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Han","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Nankai University, Tianjin 300350, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibin","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Xu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-5479","authenticated-orcid":false,"given":"Xichuan","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Animal and Plant Resistance, College of Life Sciences, Tianjin Normal University, Tianjin 300387, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"108459","DOI":"10.1016\/j.pharmthera.2023.108459","article-title":"Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance","volume":"248","author":"Miners","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2016.01.009","article-title":"The role of glucuronidation in drug resistance","volume":"159","author":"Mazerska","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dmpk.2014.12.001","article-title":"A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development","volume":"30","author":"Oda","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_4","unstructured":"FDA (2020). In Vitro Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry, FDA."},{"key":"ref_5","unstructured":"National Pharmacopoeia Commission (2020). Cortex Fraxini (Qinpi). Pharmacopoeia of the People\u2019s Republic of China, China Medical Science Press. [2020 ed.]."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chroma.2005.03.023","article-title":"Isolation and purification of coumarin compounds from Cortex fraxinus by high-speed counter-current chromatography","volume":"1072","author":"Liu","year":"2005","journal-title":"J. Chromatogr. A"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"117849","DOI":"10.1016\/j.jep.2024.117849","article-title":"Fraxini cortex: Progresses in phytochemistry, pharmacology and ethnomedicinal uses","volume":"325","author":"Zheng","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchromb.2016.04.042","article-title":"Simultaneous determination of nine coumarins in rat plasma by HPLC-MS\/MS for pharmacokinetics studies following oral administration of Fraxini Cortex extract","volume":"1025","author":"Zhao","year":"2016","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2400092","DOI":"10.1002\/ardp.202400092","article-title":"Health benefits of fraxetin: From chemistry to medicine","volume":"357","author":"Ha","year":"2024","journal-title":"Arch. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1021\/np0580412","article-title":"Metabolic fate of fraxin administered orally to rats","volume":"69","author":"Yasuda","year":"2006","journal-title":"J. Nat. Prod."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2133\/dmpk.DMPK-13-RG-059","article-title":"Identification and characterization of human UDP-glucuronosyltransferases responsible for the glucuronidation of fraxetin","volume":"29","author":"Xia","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Qin, Z., Zhang, B., Yang, J., Li, S., Xu, J., Yao, Z., Zhang, X., Gonzalez, F.J., and Yao, X. (2019). The Efflux Mechanism of Fraxetin-O-Glucuronides in UGT1A9-Transfected HeLa Cells: Identification of Multidrug Resistance-Associated Proteins 3 and 4 (MRP3\/4) as the Important Contributors. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00496"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104510","DOI":"10.1016\/j.phrs.2019.104510","article-title":"Potential of herb-drug\/herb interactions between substrates and inhibitors of UGTs derived from herbal medicines","volume":"150","author":"Liu","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"110248","DOI":"10.1016\/j.cbi.2022.110248","article-title":"Inhibition of UGT1A1*1 and UGT1A1*6 catalyzed glucuronidation of SN-38 by silybins","volume":"368","author":"Li","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14740330903405593","article-title":"Clinically based evidence of drug-herb interactions: A systematic review","volume":"9","author":"Kennedy","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2125.2012.04350.x","article-title":"Herb-drug interactions: An overview of systematic reviews","volume":"75","author":"Posadzki","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/BF03261975","article-title":"Safety monitoring of herb-drug interactions: A component of pharmacovigilance","volume":"35","author":"Skalli","year":"2012","journal-title":"Drug Saf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","article-title":"AlphaFold protein structure database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models","volume":"50","author":"Varadi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_20","unstructured":"Cayman Chemical (2026, June 10). Fraxetin (Item No. 28011), Product Information. Available online: https:\/\/www.caymanchem.com\/product\/28011."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"ref_23","first-page":"1","article-title":"Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists","volume":"46","author":"Copeland","year":"2005","journal-title":"Methods Biochem. Anal."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"105290","DOI":"10.1016\/j.isci.2022.105290","article-title":"Machine learning and structure-based modeling for the prediction of UDP-glucuronosyltransferase inhibition","volume":"25","author":"Dudas","year":"2022","journal-title":"iScience"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1021\/acsomega.0c00205","article-title":"Homology Modeling of Human Uridine-5\u2032-diphosphate-glucuronosyltransferase 1A6 Reveals Insights into Factors Influencing Substrate and Cosubstrate Binding","volume":"5","author":"Smith","year":"2020","journal-title":"ACS Omega"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0006-3495(03)74962-5","article-title":"MD simulation of protein-ligand interaction: Formation and dissociation of an insulin-phenol complex","volume":"84","author":"Swegat","year":"2003","journal-title":"Biophys. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/minf.201100135","article-title":"Free Energy Calculations by the Molecular Mechanics Poisson-Boltzmann Surface Area Method","volume":"31","author":"Homeyer","year":"2012","journal-title":"Mol. Inform."},{"key":"ref_28","first-page":"3723","article-title":"Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea","volume":"54","author":"Gupta","year":"1994","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","article-title":"Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism","volume":"65","author":"Iyer","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/psp4.12047","article-title":"Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers","volume":"4","author":"Gufford","year":"2015","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1124\/dmd.115.065870","article-title":"Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions","volume":"43","author":"Pattanawongsa","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1124\/dmd.107.016196","article-title":"Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme","volume":"35","author":"Kassahun","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","article-title":"Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: Implications of genetic variants on pharmacokinetics and hyperbilirubinemia","volume":"18","author":"Peer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_34","first-page":"98","article-title":"Guidelines for diagnosis and treatment of gout and hyperuricemia with integrated traditional Chinese and Western medicine","volume":"64","author":"Liu","year":"2023","journal-title":"J. Tradit. Chin. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome","volume":"333","author":"Bosma","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/03602530903209288","article-title":"Interindividual variability in hepatic drug glucuronidation: Studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system","volume":"42","author":"Court","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpba.2007.12.009","article-title":"Simultaneous analysis of coumarins and secoiridoids in Cortex Fraxini by high-performance liquid chromatography-diode array detection-electrospray ionization tandem mass spectrometry","volume":"47","author":"Zhou","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e3934","DOI":"10.1002\/bmc.3934","article-title":"Comparative pharmacokinetic study of the main components of cortex fraxini after oral administration in normal and hyperuricemic rats","volume":"31","author":"Wang","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.toxlet.2022.01.007","article-title":"Potential interactions among myricetin and dietary flavonols through the inhibition of human UDP-glucuronosyltransferase in vitro","volume":"358","author":"Li","year":"2022","journal-title":"Toxicol. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human udp-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/ja01318a036","article-title":"The determination of enzyme dissociation constants","volume":"56","author":"Lineweaver","year":"1934","journal-title":"J. Am. Chem. Soc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1042\/bj0550170","article-title":"The determination of enzyme inhibitor constants","volume":"55","author":"Dixon","year":"1953","journal-title":"Biochem. J."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Alhumaid, N.K., and Tawfik, E.A. (2024). Reliability of AlphaFold2 models in virtual drug screening: A focus on selected class A GPCRs. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251810139"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13321-025-01067-4","article-title":"Evaluating ligand docking methods for drugging protein-protein interfaces: Insights from AlphaFold2 and molecular dynamics refinement","volume":"17","year":"2025","journal-title":"J. Cheminform."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: New docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: Expanding the scope of the protein-ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"114502","DOI":"10.1063\/5.0019056","article-title":"A fast and high-quality charge model for the next generation general AMBER force field","volume":"153","author":"He","year":"2020","journal-title":"J. Chem. Phys."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS","volume":"17","author":"Valiente","year":"2021","journal-title":"J. Chem. Theory Comput."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/968\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:36:32Z","timestamp":1782876992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060968"],"URL":"https:\/\/doi.org\/10.3390\/ph19060968","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}